This content is from: Research

Health Care – Biotechnology: First

Mark Schoenebaum
ISI Group
“He does a phenomenal job of making sure investors understand the significant issues.”

Mark Schoenebaum marks his eighth straight top ranking; the ISI Group analyst also takes third in Pharmaceuticals/Major. “Regardless of whether we agree on the stock call, I can trust that he has done his homework, allowing us to have an informed debate,” maintains one fan. Schoenebaum, 39, says he will remain cautious until after the November U.S. elections: If Republican Mitt Romney wins the presidency and the Patient Protection and Affordable Care Act is dismantled, the sector will face an unclear future — at least in the near term. “An Obama victory is better for stocks because it reduces uncertainty,” he says. Schoenebaum, who covers ten names, highlighted his buy on Amgen in November, at $57.57, citing the Thousand Oaks, California–based company’s improved use of capital and increased pipeline visibility. In April, when Amgen announced that it was launching Phase 3 clinical trials on its sclerostin antibody, used in the treatment of postmenopausal osteoporosis, he pounded the table. By the end of August, the stock had soared 45.8 percent, to $83.92, since the November reiteration.


Related Content